[HTML][HTML] The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism
…, LN Varghese, GM Tannahill, EC Hatchell, IJ Majewski… - Immunity, 2013 - cell.com
Mixed lineage kinase domain-like (MLKL) is a component of the "necrosome," the multiprotein
complex that triggers tumor necrosis factor (TNF)-induced cell death by necroptosis. To …
complex that triggers tumor necrosis factor (TNF)-induced cell death by necroptosis. To …
[HTML][HTML] Robust hyperparameter estimation protects against hypervariable genes and improves power to detect differential expression
One of the most common analysis tasks in genomic research is to identify genes that are
differentially expressed (DE) between experimental conditions. Empirical Bayes (EB) statistical …
differentially expressed (DE) between experimental conditions. Empirical Bayes (EB) statistical …
Taming the dragon: genomic biomarkers to individualize the treatment of cancer
IJ Majewski, R Bernards - Nature medicine, 2011 - nature.com
The gradual shift from cytotoxic drugs to highly selective, targeted therapeutic agents for
cancer requires a parallel effort to characterize cancers at the molecular level to guide the …
cancer requires a parallel effort to characterize cancers at the molecular level to guide the …
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
…, DCS Huang, AW Roberts, IJ Majewski… - Blood, The Journal …, 2020 - ashpublications.org
The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose
cytarabine represents an important new therapy for older or unfit patients with acute myeloid …
cytarabine represents an important new therapy for older or unfit patients with acute myeloid …
Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia
…, T Nguyen, Z Xu, C Flensburg, TE Lew, IJ Majewski… - Cancer discovery, 2019 - AACR
… Flensburg, and IJ Majewski have received remuneration from the Walter and Eliza Hall
Institute. TE Lew is an employee of the Walter and Eliza Hall Institute of Medical Research and …
Institute. TE Lew is an employee of the Walter and Eliza Hall Institute of Medical Research and …
ChIP-seq analysis reveals distinct H3K27me3 profiles that correlate with transcriptional activity
…, ME Blewitt, A Oshlack, IJ Majewski - Nucleic acids …, 2011 - academic.oup.com
Transcriptional control is dependent on a vast network of epigenetic modifications. One
epigenetic mark of particular interest is tri-methylation of lysine 27 on histone H3 (H3K27me3), …
epigenetic mark of particular interest is tri-methylation of lysine 27 on histone H3 (H3K27me3), …
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism
…, D Westerman, EG Si, IJ Majewski… - Blood, The Journal …, 2016 - ashpublications.org
BCL2 blunts activation of the mitochondrial pathway to apoptosis, and high-level expression
is required for chronic lymphocytic leukemia (CLL) survival. Venetoclax (ABT-199) is a small…
is required for chronic lymphocytic leukemia (CLL) survival. Venetoclax (ABT-199) is a small…
[HTML][HTML] PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2–targeted therapies in breast cancer
IJ Majewski, P Nuciforo, L Mittempergher… - Journal of Clinical …, 2015 - ncbi.nlm.nih.gov
Purpose We investigated whether mutations in the gene encoding the phosphatidylinositol 3-kinase
(PI3K) catalytic subunit (PIK3CA) correlates with response to neoadjuvant human …
(PI3K) catalytic subunit (PIK3CA) correlates with response to neoadjuvant human …
An α‐E‐catenin (CTNNA1) mutation in hereditary diffuse gastric cancer
IJ Majewski, I Kluijt, A Cats, TS Scerri… - The Journal of …, 2013 - Wiley Online Library
Diffuse gastric cancers typically present as late‐stage tumours and, as a result, the 5 year
survival rate is poor. Some gastric cancers are hereditary and these tend to be of the diffuse …
survival rate is poor. Some gastric cancers are hereditary and these tend to be of the diffuse …
Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive …
…, S Fleming, FC Brown, S Loo, IJ Majewski… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE The B-cell lymphoma 2 (BCL-2) inhibitor venetoclax has an emerging role in
acute myeloid leukemia (AML), with promising response rates in combination with …
acute myeloid leukemia (AML), with promising response rates in combination with …